Skip to content
The Peptide Effect
Comparison

MK-677 (Ibutamoren) vs Ipamorelin

MK-677 (ibutamoren) and ipamorelin both stimulate growth hormone release through ghrelin receptor activation, but they differ dramatically in pharmacology, administration, and side effect profiles. MK-677 is an oral, non-peptide small molecule with a 24-hour half-life that produces sustained, round-the-clock GH and IGF-1 elevation. Ipamorelin is an injectable pentapeptide with a 2-hour half-life that creates clean, pulsatile GH spikes with virtually no impact on cortisol, prolactin, or appetite — making it the more selective and side-effect-friendly option despite requiring injections.

Side-by-side comparison diagram of MK-677 (Ibutamoren) and Ipamorelin mechanisms of action
Conceptual comparison — not to scale

Head-to-Head Comparison

CriteriaMK-677 (Ibutamoren)Ipamorelin
Chemical classNon-peptide small molecule (growth hormone secretagogue)Pentapeptide (growth hormone releasing peptide / GHRP)
Route of administrationOral (capsule or liquid) — major convenience advantageSubcutaneous injection — requires reconstitution and syringes
Primary mechanismGhrelin receptor (GHS-R1a) agonist with sustained activationSelective ghrelin receptor (GHS-R1a) agonist with pulsatile activation
Half-life~24 hours — once-daily oral dosing~2 hours — requires 1–3 daily injections
GH release patternSustained 24-hour GH and IGF-1 elevationAcute pulsatile GH spikes mimicking natural secretion
Typical dosage10–25 mg orally, once daily (usually before bed)200–300 mcg subcutaneous, 1–3× daily
Appetite stimulationSignificant — can increase appetite dramatically (ghrelin-like effect)Minimal — highly selective, does not significantly increase hunger
Cortisol/prolactin impactCan moderately elevate cortisol; mild prolactin increase reportedVirtually no cortisol or prolactin elevation at standard doses
Effect on blood sugarCan increase fasting glucose and reduce insulin sensitivity with chronic useNo significant impact on blood glucose or insulin sensitivity
Water retentionCommon — noticeable water retention and bloating, especially in first weeksMinimal water retention
IGF-1 elevationRobust and sustained — 40–90% increase in IGF-1 documented in clinical trialsModerate and transient — peaks post-injection then returns to baseline
Research depthExtensive — multiple Phase II clinical trials in elderly, post-surgical, and obese populationsModerate — clinical studies focused on GH release kinetics and post-surgical recovery

When to Choose Each

Choose MK-677 (Ibutamoren)

Users who want oral convenience (no injections), those seeking maximum sustained IGF-1 elevation, bulking phases where increased appetite is a benefit, individuals who tolerate water retention well

Choose Ipamorelin

Users who prioritize clean GH release with minimal side effects, those sensitive to blood sugar or cortisol changes, cutting phases where appetite control matters, athletes wanting pulsatile GH for recovery

Verdict

The choice between MK-677 and ipamorelin comes down to convenience versus selectivity. MK-677 wins on ease of use — oral dosing, once daily, no needles — and produces more robust, sustained IGF-1 elevation. However, it comes with meaningful side effects: increased appetite, water retention, elevated blood sugar, and potential insulin resistance with chronic use. Ipamorelin is the cleaner compound — virtually no off-target effects — but requires daily subcutaneous injections. For pure GH optimization with minimal side effects, ipamorelin is superior. For users who want oral convenience and maximum IGF-1 elevation and can manage the metabolic side effects, MK-677 is a pragmatic choice.

References

  1. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism (1998) — PubMed
  2. Two-year effects of ibutamoren on bone mineral density, body composition, and markers of bone turnover in elderly (2001) — PubMed
  3. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/IGF-I axis (1997) — PubMed
  4. Ipamorelin, the first selective growth hormone secretagogue (1998) — PubMed
  5. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial (2008) — PubMed

Frequently Asked Questions

Is MK-677 actually a peptide?
No. MK-677 (ibutamoren) is a non-peptide small molecule that mimics ghrelin at the GHS-R1a receptor. Unlike true peptides, it survives oral digestion and has a long half-life. It is often grouped with GH peptides because of its similar mechanism and user base, but pharmacologically it is a distinct class of compound — a peptidomimetic growth hormone secretagogue.
Can MK-677 cause diabetes or insulin resistance?
Chronic MK-677 use has been shown to increase fasting blood glucose and reduce insulin sensitivity in some clinical trials, particularly in elderly and obese populations. These effects are generally reversible upon discontinuation. Users should monitor fasting glucose and HbA1c, especially if they have pre-existing metabolic risk factors. Ipamorelin does not carry this risk.
Can I stack MK-677 with ipamorelin?
While both act on the ghrelin receptor, some users combine low-dose MK-677 (10 mg) for baseline IGF-1 elevation with ipamorelin pulses for acute GH spikes. However, this is not as synergistic as combining a GHRH analog (CJC-1295, sermorelin) with ipamorelin, because MK-677 and ipamorelin share the same receptor pathway rather than complementing different pathways.
How long can I safely take MK-677?
Clinical trials have studied MK-677 for up to 2 years continuously. However, most users cycle 8–12 weeks on, 4 weeks off to manage side effects (water retention, appetite, insulin sensitivity). Blood work monitoring every 3 months is strongly recommended, with particular attention to fasting glucose, insulin, and IGF-1 levels.
Which is more affordable, MK-677 or ipamorelin?
MK-677 is generally more affordable on a per-month basis. Research-grade MK-677 typically costs $30 to $80 per month since it is an oral compound that is relatively simple to manufacture. Ipamorelin at research grade runs $40 to $80 per month but also requires syringes, bacteriostatic water for reconstitution, and alcohol swabs, adding to the total cost. Clinic-prescribed ipamorelin is often $150 to $350 per month. However, cost should not be the primary deciding factor — the compounds have meaningfully different side effect profiles that may make one or the other more appropriate. Consulting a healthcare provider about which option suits individual health goals is recommended.

Explore next